An Oral Therapy for Clinically Isolated Syndrome

The benefit of oral disease-modifying therapies approved for treatment of relapsing remitting multiple sclerosis (RRMS) has yet to be established in the clinically isolated syndrome (CIS) population. Now, investigators have evaluated the efficacy and safety of oral teriflunomide (FDA-approved for treatment of clinically definite relapsing-remitting MS) in patients with CIS. In this randomized, double-blind, placebo-controlled, parallel-group study, 614 patients aged 18 to 55 with CIS (a first demyelinating attack with evidence of subclinical disease activity on magnetic resonance imaging [MRI]) were randomized 1:1:1 to receive once-daily teriflunomide 14 mg, teriflunomide 7 mg, or placebo for up to 108 weeks. After 108 weeks or after a seco…